Trial Profile
Pilot Trial of Orencia in Myasthenia Gravis Patients Inadequately Responsive to Conventional Immunotherapy
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 20 Nov 2019 Status changed from recruiting to discontinued.
- 13 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Apr 2020.
- 13 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2020.